Theravance Biopharma Inc

Stock Chart, Company Information, and Scan Results

$16.26(as of May 27, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Theravance Biopharma Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$16.26
Ticker SymbolTBPH
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees90
CountyUSA
Market Cap$846.0M

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Theravance Biopharma Inc In Our Stock Scanner

As of May 28, 2026
example chart graphic
Scan Name: Low PE RatiosScan Type: Stock Fundamentals
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Double BottomScan Type: Chart Pattern Scans
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.